Clinical Trial of a Calcium Channel Blocker in Patients with Aneurysmal Subarachnoid Hemorrhage
Yonsei Medical Journal
;
: 126-130, 1987.
Article
in English
| WPRIM
| ID: wpr-106499
ABSTRACT
Forty-three patients with aneurysmal subarachnoid hemorrhage entered a nimodipine trial in the Department of Neurosurgery, Yonsei university to determine the efficacy of the drug in preventing vasospasm and to evaluate the tolerability of this calcium channel blocker. Thirty-three patients completed the study. Treatment was started within four days of initial bleeding and continued for two weeks. Delayed neurological deficits developed in seven of the 33 patients-four from vasospasm, two from elevated intracranial pressure, and one from recurrent bleeding. The incidence of symptomatic vasospasm which developed after calcium channel blocker (nimodipine) treatment was 12.1%, which is about one third of the rate experienced at our department during the past five years (33.2%). Twenty-five patients were operated on without surgical mortality and the morbidity rate was 8%. Side effects due to nimodipine treatment were reversible and insignificant. This study suggests that treatment with a calcium channel blocker that has a selective cerebrovascular effect may prevent or reduce the incidence of delayed ischemic deficits in patients with aneurysmal subarachnoid hemorrhage.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Subarachnoid Hemorrhage
/
Nimodipine
/
Ischemic Attack, Transient
/
Prospective Studies
/
Clinical Trials as Topic
Type of study:
Controlled clinical trial
/
Observational study
Limits:
Humans
Language:
English
Journal:
Yonsei Medical Journal
Year:
1987
Type:
Article
Similar
MEDLINE
...
LILACS
LIS